The optimal first-line treatment for extra-nodal NK/T-cell lymphoma (ENKTL) has not been well-defined. This phase II study aimed to evaluate the efficacy and safety of pegaspargase, cyclophosphamide, vincristine, etoposide and prednisone (COEPL) regimen combined with radiotherapy for patients with newly diagnosed ENKTL.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
150
Cyclophosphamide 750 mg/m2 intravenously on day 1, vincristine 1.4 mg/m2 intravenously on day1, etoposide 60mg/m2 intravenously on days 1-3; pegaspargase 2500IU/m2 intramuscularly on day 2, prednisone 100mg orally on days 1-5.
Peking University Cancer Hospital & Institute
Beijing, Beijing Municipality, China
RECRUITINGComplete response rate
Time frame: 1 year
Overall response rate
Time frame: 1 year
Progression-free survival
Time frame: 3-year
Overall survival
Time frame: 3-year
Adverse events
Time frame: 1-year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.